ISAL 2019 | MDM2 inhibition in AML: trial updates
The inhibition of MDM2 blocks the MDM2-p53 protein-protein interaction, allowing p53 to signal for apoptosis; however, there have been challenges with implementing this approach as a therapy. Here, Marina Konopleva, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the latest data regarding MDM2 inhibitor therapy for acute myeloid leukemia (AML); in combination with cytarabine (MIRROS; NCT02545283) or in combination with venetoclax (NCT02670044). This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
Get great new content delivered to your inboxSign up